Windward Bio Group AG filed a Form S-8 registration statement with the U.S. Securities and Exchange Commission on November 13, 2026, covering 513,082 common shares issuable to selling shareholders under its Amended and Restated 2025 Equity Incentive Plan, alongside a reoffer prospectus permitting those shareholders to resell the shares.

Key Highlights

  • 513,082 common shares are covered by the reoffer prospectus, each with a nominal value of CHF 0.015 per share.
  • Shares derive from restricted share units granted under the Windward Bio Group AG Amended and Restated 2025 Equity Incentive Plan.
  • IPO price was $17.00 per share, according to the Form F-1 registration statement declared effective on November 12, 2026.
  • Listing approved on Nasdaq Global Select Market under the symbol "WWB."
  • Windward Bio will receive no proceeds from any resales made by the selling shareholders under this registration.
  • Resale volume limits apply: each selling shareholder may not reoffer more than the amount specified in Rule 144(e) during any three-month period.
  • Lock-up agreements entered into with IPO underwriters may restrict certain selling shareholders from selling before those agreements expire, subject to any applicable release provisions.

Windward Bio Group AG Registers RSU Shares for Resale Following November 2026 IPO

According to the filing, Windward Bio Group AG, a Swiss corporation (Aktiengesellschaft) incorporated in Basel, Switzerland, submitted an S-8 registration statement that includes a reoffer prospectus prepared in accordance with Part I of Form F-3. The reoffer prospectus covers 513,082 common shares, each with a nominal value of CHF 0.015, that were or will be acquired by selling shareholders upon settlement of restricted share units granted under the company's Amended and Restated 2025 Equity Incentive Plan. The selling shareholders are described as directors, officers, or other employees of the registrant.

The filing states that the company's Form F-1 registration statement was initially filed with the SEC on October 23, 2026, and was declared effective on November 12, 2026, with an initial public offering price of $17.00 per share. The company disclosed that it has been approved to list its common shares on the Nasdaq Global Select Market under the symbol "WWB." The filing identifies the company as a non-accelerated filer, a smaller reporting company, and an emerging growth company under federal securities laws.

The filing notes that the selling shareholders may sell their shares through open market transactions, negotiated transactions, or a combination of methods, and that sale prices and any commissions will vary by transaction. The company stated that it will not receive any proceeds from these resales, and that selling shareholders will bear all sales commissions and similar expenses. The filing also notes that certain selling shareholders may be subject to lock-up agreements with the IPO underwriters, though release provisions described in the Form F-1 may allow earlier sales in some cases.

What Was Disclosed

Windward Bio Group AG registered 513,082 common shares for potential resale by employee selling shareholders under its 2025 Equity Incentive Plan via an S-8 and accompanying reoffer prospectus filed November 13, 2026, shortly after its IPO at $17.00 per share.